News

ascopubs.org6d
Immunotherapeutic response score to predict prognosis for unresectable hepatocellular carcinoma with immune checkpoint inhibitors-based conversion treatment.
Effect of cDC2 licensing by CCL5+ Th1 cells following BCL9/BCL9L inhibition on CD8+ T cell cross-priming for enhanced anti-tumor responses. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
ascopubs.org6d
Comparison of efficacy and safety of lenvatinib vs. apatinib in combination with hepatic arterial infusion chemotherapy and immune checkpoint inhibitors for unresectable ...
Effect of cDC2 licensing by CCL5+ Th1 cells following BCL9/BCL9L inhibition on CD8+ T cell cross-priming for enhanced anti-tumor responses. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
PNAS25d
The developmental factor TBX3 engages with the Wnt/β-catenin transcriptional complex in colorectal cancer to regulate metastasis genes
Dysregulated Wnt signaling is a well-established driver of colorectal carcinogenesis. However, its pivotal role in normal intestinal stem cell homeostasis has posed significant challenges for its ...
C&EN19d
α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53–MDM2/MDMX Protein–Protein Interactions
Department of Chemistry, University of South Florida, 4202 E. Fowler Avenue, Tampa, Florida 33620, United States ...
asco.org11d
Abstract Details
Disclaimer This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information ...
Targeted Oncology11d
GENOMIC TESTING
Data from the phase 2 ROME trial were presented by Andrea Botticelli, MD, during the ESMO Targeted Anticancer Therapies Congress 2025.